Effect of glucose variability on the mortality of adults aged 75 years and over during the first year of the COVID-19 pandemic

Miguel A. Salinero-Fort,F. Javier San Andrés-Rebollo,Juan Cárdenas-Valladolid,José Mostaza,Carlos Lahoz,Fernando Rodriguez-Artalejo,Paloma Gómez-Campelo,Pilar Vich-Pérez,Rodrigo Jiménez-García,José M. de-Miguel-Yanes,Javier Maroto-Rodriguez,Belén Taulero-Escalera,Víctor Iriarte Campo,A. Gutiérrez-Misis,E. Carrillo de Santa Pau,M. V. Castell-Alcalá,B. Álvarez-Embarba,N. Behzadi-Koochani,C. de Burgos-Lunar,P. Regueiro-Toribio,T. Gijón-Conde,on behalf of the Aged-Madrid Study Research Group
DOI: https://doi.org/10.1186/s12877-024-05149-0
IF: 4.07
2024-06-21
BMC Geriatrics
Abstract:To our knowledge, only one study has examined the association between glucose variability (GV) and mortality in the elderly population with diabetes. GV was assessed by HbA1c, and a J-shaped curve was observed in the relationship between HbA1c thresholds and mortality. No study of GV was conducted during the COVID-19 pandemic and its lockdown. This study aims to evaluate whether GV is an independent predictor of all-cause mortality in patients aged 75 years or older with and without COVID-19 who were followed during the first year of the COVID-19 pandemic and its lockdown measures.
geriatrics & gerontology,gerontology
What problem does this paper attempt to address?